** Shares of drugmaker Eli Lilly rise 10.2% to $810.13 premarket
** Co says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial
** U.S.-listed shares of Lilly's obesity rival Novo Nordisk NOVOb.CO down 3.8%
** Up to last close, LLY down 4.8% YTD
(Reporting by Christy Santhosh in Bengaluru)
((Christy.Santhosh@thomsonreuters.com))